Stock 4892 CYFUSE BIOMEDICAL K.K.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cyfuse Biomedical K.K.

Equities

4892

JP3311800001

Biotechnology & Medical Research

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-17 am EDT 		5-day change 1st Jan Change
732 JPY +3.68% Intraday chart for Cyfuse Biomedical K.K. +0.41% -3.94%
2023 Certain Common Stock of Cyfuse Biomedical K.K. are subject to a Lock-Up Agreement Ending on 1-JUN-2023. CI
2023 Certain Common Stock of Cyfuse Biomedical K.K. are subject to a Lock-Up Agreement Ending on 28-FEB-2023. CI

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 9,559 5,957
Enterprise Value (EV) 1 6,029 2,997
P/E ratio -7.34 x -10.1 x
Yield - -
Capitalization / Revenue 25.6 x 97.7 x
EV / Revenue 16.1 x 49.1 x
EV / EBITDA -16,654,247 x -4,561,313 x
EV / FCF -13,163,400 x -6,706,087 x
FCF Yield -0% -0%
Price to Book 2.22 x 1.86 x
Nbr of stocks (in thousands) 7,347 7,817
Reference price 2 1,301 762.0
Announcement Date 3/28/23 3/27/24
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 137 708 374 61
EBITDA - - -362 -657
EBIT 1 -372 71 -425 -697
Operating Margin -271.53% 10.03% -113.64% -1,142.62%
Earnings before Tax (EBT) 1 -327 144 -471 -586
Net income 1 -329 142 -473 -589
Net margin -240.15% 20.06% -126.47% -965.57%
EPS 2 -657.3 283.7 -177.3 -75.39
Free Cash Flow - - -458 -446.9
FCF margin - - -122.46% -732.58%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 10/27/22 10/27/22 3/28/23 3/27/24
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period:
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 1,545 1,846 3,530 2,960
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - -458 -447
ROE (net income / shareholders' equity) - 8.23% -16.7% -16.9%
ROA (Net income/ Total Assets) - 1.83% -7.12% -9.65%
Assets 1 - 7,747 6,643 6,104
Book Value Per Share 2 3,095 3,796 585.0 409.0
Cash Flow per Share 2 4,140 4,821 689.0 495.0
Capex - - 228 19
Capex / Sales - - 60.96% 31.15%
Announcement Date 10/27/22 10/27/22 3/28/23 3/27/24
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CYFUSE BIOMEDICAL K.K. Stock Cyfuse Biomedical K.K.
-3.94% 35.9M
MODERNA, INC. Stock Moderna, Inc.
+34.07% 50.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.80% 42.82B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.03B
CELLTRION, INC. Stock Celltrion, Inc.
-4.96% 29.55B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.95% 26.11B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.61% 19.13B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+9.35% 13.05B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.66% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+23.93% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 4892 Stock
  4. Financials Cyfuse Biomedical K.K.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW